Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.

M. Alcoceba, L. Marin, A. Balanzategui, M.E. Sarasquete, PhD, P. Martin-Jimenez, PhD, M.C. Chillon, PhD, M. Vargas, R. Corral, MD, E. Perez, MD, J. Fernandez-Calvo, MD, PhD, A. Martinez, MD, PhD, J.M. Hernandez, MD, PhD, Joan Blade, MD, PhD, J.J. Lahuerta, MD, PhD, R. Garcia-Sanz, MD, PhD, M. Gonzalez, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 1481.

https://doi.org/10.1182/blood.V110.11.1481.1481

Published: 2007

Journal Articles

Clinical Efficacy of Bortezomib Based Therapy in Plasma Cell Leukemias.

Adrian Alegre, B. Aguado, J.J. Lahuerta, C. Cervero, A. Oriol, A. Abella, R. Carrion, R. Renat, J.A. Hernandez-Rivas, J. de la Rubia, M.V. Mateos, R. Garcia-Sanz, R. Rodriguez-Notario, B. Navas, J.M. Fernandez-Rañada, J.F. San Miguel

Blood (2007) 110 (11): 2726.

https://doi.org/10.1182/blood.V110.11.2726.2726

Published: 2007

Journal Articles

Preliminary Report from an Exploratory Phase II Trial with Plitidepsin (Aplidin®) in Patients with Refractory/Relapsed Multiple Myeloma.

M. V. Mateos, MD, J. Blade, MD, F. Prosper, MD, J. J. Lahuerta, MD, R. Garcia-Sanz, MD, M. Cibeira, MD, L. Rusiñol, MD, F. Escalante, MD, M. Ruiz, MD, P. G. Richardson, MD, J. F. San Miguel, MD

Blood (2005) 106 (11): 2569.

https://doi.org/10.1182/blood.V106.11.2569.2569

Published: 2005

Journal Articles

High-Dose Therapy/Stem Cell Support (HDT), Including Tandem Transplant, for Primary Refractory Multiple Myeloma (MM): Results from the Spanish Myeloma Group (PETHEMA/GEM) in 49 Patients.

L. Rosinol, R. Garcia-Sanz, J. J. Lahuerta, M. Hernandez-Garcia, A. Sureda, J. de la Rubia, J. M. Ribera, B. Hernandez-Ruiz, D. Carreras, I. Navarro, J. C. Garcia-Ruiz, S. Gardella, J. Garcia-Larana, J. Diaz-Mediavilla, J. F. San Miguel, J. Blade

Blood (2005) 106 (11): 5472.

https://doi.org/10.1182/blood.V106.11.5472.5472

Published: 2005

Journal Articles

A new staging system for multiple myeloma based on the number of S- phase plasma cells

JF San Miguel, R Garcia-Sanz, M Gonzalez, MJ Moro, JM Hernandez, F Ortega, D Borrego, M Carnero, F Casanova, R Jimenez

Blood (1995) 85 (2): 448–455.

https://doi.org/10.1182/blood.V85.2.448.448

Published: 1995

NARROW

Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.

Clinical Efficacy of Bortezomib Based Therapy in Plasma Cell Leukemias.

Preliminary Report from an Exploratory Phase II Trial with Plitidepsin (Aplidin®) in Patients with Refractory/Relapsed Multiple Myeloma.

High-Dose Therapy/Stem Cell Support (HDT), Including Tandem Transplant, for Primary Refractory Multiple Myeloma (MM): Results from the Spanish Myeloma Group (PETHEMA/GEM) in 49 Patients.

A new staging system for multiple myeloma based on the number of S- phase plasma cells

Email alerts

ASH Publications

American Society of Hematology

Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.

Clinical Efficacy of Bortezomib Based Therapy in Plasma Cell Leukemias.

Preliminary Report from an Exploratory Phase II Trial with Plitidepsin (Aplidin®) in Patients with Refractory/Relapsed Multiple Myeloma.

High-Dose Therapy/Stem Cell Support (HDT), Including Tandem Transplant, for Primary Refractory Multiple Myeloma (MM): Results from the Spanish Myeloma Group (PETHEMA/GEM) in 49 Patients.

A new staging system for multiple myeloma based on the number of S- phase plasma cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only